Elranatamab for AL amyloidosis that has returned or not responded
Treatments studied
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a drug called elranatamab for people with AL amyloidosis whose disease has come back or is not responding to treatment. The goal is to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with AL amyloidosis and have tried at least one prior treatment that didn't work or stopped working.
- You are 18 years or older.
- You are able to do most daily activities on your own (ECOG performance status 0-2).
- Your blood counts and kidney and liver function are within certain ranges.
- You have not had a previous treatment that targets BCMA (like certain bispecific antibodies or CAR-T therapy).
- You are willing to use contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called teclistamab for people with AL amyloidosis whose disease has not responded well to previous treatments. It aims to see if the drug can help control the disease.
This study tests belantamab mafodotin, a medicine designed to target amyloid-producing abnormal cells, in people with relapsed or refractory AL (light-chain) amyloidosis. It’s aimed at improving blood and organ-related signs of the disease after earlier treatments have stopped working.
This trial tests a new drug (a bispecific antibody) for people newly diagnosed with AL amyloidosis, a condition where abnormal proteins build up and damage organs. The drug aims to target and clear these abnormal cells to help reduce organ damage.
This trial tests an experimental treatment using your own immune cells, modified in the lab, to target and destroy the cells that cause AL amyloidosis. It is for people who are newly diagnosed and have severe heart involvement, with the goal of slowing or stopping the disease.
This trial tests a new drug called teclistamab for people newly diagnosed with advanced (stage IIIB) AL amyloidosis, a condition where abnormal proteins build up and damage organs. The goal is to see if teclistamab can help control the disease.
This trial tests a combination of two drugs (teclistamab and daratumumab) for people with AL amyloidosis who have not had prior treatment. The goal is to see if this combination can safely and effectively reduce the abnormal protein deposits in organs.
Hear when a new AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.